S&P 500   3,956.77 (+0.58%)
DOW   33,700.33 (+0.30%)
QQQ   283.11 (+0.92%)
AAPL   142.14 (+0.85%)
MSFT   246.61 (+0.92%)
META   115.70 (+1.55%)
GOOGL   94.06 (-0.93%)
AMZN   89.86 (+1.58%)
TSLA   172.94 (-0.63%)
NVDA   169.50 (+5.15%)
NIO   13.35 (+6.12%)
BABA   94.00 (+6.42%)
AMD   69.93 (-0.30%)
T   19.15 (-0.78%)
MU   55.25 (+2.66%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.32 (-1.98%)
DIS   92.52 (+0.40%)
AMC   6.16 (+1.82%)
PYPL   74.33 (-0.12%)
PFE   51.73 (+2.97%)
NFLX   308.72 (+0.10%)
S&P 500   3,956.77 (+0.58%)
DOW   33,700.33 (+0.30%)
QQQ   283.11 (+0.92%)
AAPL   142.14 (+0.85%)
MSFT   246.61 (+0.92%)
META   115.70 (+1.55%)
GOOGL   94.06 (-0.93%)
AMZN   89.86 (+1.58%)
TSLA   172.94 (-0.63%)
NVDA   169.50 (+5.15%)
NIO   13.35 (+6.12%)
BABA   94.00 (+6.42%)
AMD   69.93 (-0.30%)
T   19.15 (-0.78%)
MU   55.25 (+2.66%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.32 (-1.98%)
DIS   92.52 (+0.40%)
AMC   6.16 (+1.82%)
PYPL   74.33 (-0.12%)
PFE   51.73 (+2.97%)
NFLX   308.72 (+0.10%)
S&P 500   3,956.77 (+0.58%)
DOW   33,700.33 (+0.30%)
QQQ   283.11 (+0.92%)
AAPL   142.14 (+0.85%)
MSFT   246.61 (+0.92%)
META   115.70 (+1.55%)
GOOGL   94.06 (-0.93%)
AMZN   89.86 (+1.58%)
TSLA   172.94 (-0.63%)
NVDA   169.50 (+5.15%)
NIO   13.35 (+6.12%)
BABA   94.00 (+6.42%)
AMD   69.93 (-0.30%)
T   19.15 (-0.78%)
MU   55.25 (+2.66%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.32 (-1.98%)
DIS   92.52 (+0.40%)
AMC   6.16 (+1.82%)
PYPL   74.33 (-0.12%)
PFE   51.73 (+2.97%)
NFLX   308.72 (+0.10%)
S&P 500   3,956.77 (+0.58%)
DOW   33,700.33 (+0.30%)
QQQ   283.11 (+0.92%)
AAPL   142.14 (+0.85%)
MSFT   246.61 (+0.92%)
META   115.70 (+1.55%)
GOOGL   94.06 (-0.93%)
AMZN   89.86 (+1.58%)
TSLA   172.94 (-0.63%)
NVDA   169.50 (+5.15%)
NIO   13.35 (+6.12%)
BABA   94.00 (+6.42%)
AMD   69.93 (-0.30%)
T   19.15 (-0.78%)
MU   55.25 (+2.66%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.32 (-1.98%)
DIS   92.52 (+0.40%)
AMC   6.16 (+1.82%)
PYPL   74.33 (-0.12%)
PFE   51.73 (+2.97%)
NFLX   308.72 (+0.10%)
NASDAQ:ANEB

Anebulo Pharmaceuticals - ANEB Stock Forecast, Price & News

$3.04
-0.15 (-4.70%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.04
$3.37
50-Day Range
$1.79
$3.39
52-Week Range
$1.77
$7.89
Volume
6,300 shs
Average Volume
8,640 shs
Market Capitalization
$77.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Anebulo Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
163.2% Upside
$8.00 Price Target
Short Interest
Healthy
0.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of Anebulo Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

545th out of 1,022 stocks

Pharmaceutical Preparations Industry

243rd out of 499 stocks

ANEB stock logo

About Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANEB Stock News Headlines

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03
Anebulo Pharmaceuticals Inc - Stock News
See More Headlines
Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANEB Company Calendar

Last Earnings
11/10/2022
Today
12/08/2022
Next Earnings (Estimated)
2/10/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANEB
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+163.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-6,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.65 per share

Miscellaneous

Free Float
3,666,000
Market Cap
$77.92 million
Optionable
Not Optionable
Beta
-1.48

Key Executives

  • Dr. Joseph F. Lawler M.D. (Age 50)
    Ph.D., Founder & Chairman
    Comp: $11k
  • Mr. Simon J. Allen B.Sc. (Age 54)
    M.B.A., MBA, CEO & Director
    Comp: $450k
  • Mr. Rex Merchant CFA (Age 62)
    CFO & Sec.
    Comp: $275k
  • Dr. Kenneth C. Cundy Ph.D. (Age 63)
    Chief Scientific Officer
    Comp: $345.53k
  • Mr. Scott L. Anderson
    Head of Investor Relations & Public Affairs













ANEB Stock - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings
or view top-rated stocks.

What is Anebulo Pharmaceuticals' stock price forecast for 2023?

1 equities research analysts have issued 12-month price targets for Anebulo Pharmaceuticals' stock. Their ANEB share price forecasts range from $6.00 to $10.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 163.2% from the stock's current price.
View analysts price targets for ANEB
or view top-rated stocks among Wall Street analysts.

How have ANEB shares performed in 2022?

Anebulo Pharmaceuticals' stock was trading at $6.15 at the start of the year. Since then, ANEB shares have decreased by 50.6% and is now trading at $3.04.
View the best growth stocks for 2022 here
.

Are investors shorting Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 26,900 shares, a decrease of 9.4% from the October 31st total of 29,700 shares. Based on an average trading volume of 6,600 shares, the short-interest ratio is currently 4.1 days. Approximately 0.6% of the company's stock are sold short.
View Anebulo Pharmaceuticals' Short Interest
.

When is Anebulo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 10th 2023.
View our ANEB earnings forecast
.

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($0.11) earnings per share for the quarter.

When did Anebulo Pharmaceuticals IPO?

(ANEB) raised $21 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.

What is Anebulo Pharmaceuticals' stock symbol?

Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB."

Who are Anebulo Pharmaceuticals' major shareholders?

Anebulo Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LVW Advisors LLC (2.89%) and Nantahala Capital Management LLC (1.99%).
View institutional ownership trends
.

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anebulo Pharmaceuticals' stock price today?

One share of ANEB stock can currently be purchased for approximately $3.04.

How much money does Anebulo Pharmaceuticals make?

Anebulo Pharmaceuticals (NASDAQ:ANEB) has a market capitalization of $77.92 million. The company earns $-6,830,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How can I contact Anebulo Pharmaceuticals?

The official website for the company is www.anebulo.com. The company can be reached via phone at 737-203-5270 or via email at ybriggs@lhai.com.

This page (NASDAQ:ANEB) was last updated on 12/8/2022 by MarketBeat.com Staff